“More than 1,500 cancer care professionals are meeting in Orlando, Florida, March 21-23, for the NCCN 2019 Annual Conference, presented by the National Comprehensive Cancer Network® (NCCN®)—an alliance of 28 leading cancer centers. The conference offers more than 25 sessions presenting the latest treatment recommendations for lung, breast, prostate, colon, and other cancers, including new and emerging therapies. Other key topics include coordination of care, pain management during an opioid crisis, biosimilars, cancer-associated distress, biomarkers, genetic testing, and appropriate transition to end-of-life care. The keynote session highlights the benefits and challenges of treatment with new and innovative therapies (e.g. CAR T-cell) from the perspective of the patient and the clinicians caring for them.”
“Big data and machine learning have the potential to improve health, detecting disease at an earlier stage and personalizing interventions. The key ingredient, some say, is applying algorithms to population-wide datasets. But the question remains: is it enough to train smarter algorithms with broader datasets? What other approaches, diagnostics tools, and technologies do we need to accurately assess a patient’s unique needs and build a personalized intervention? A panel of experts across diagnostics, informatics, and therapeutics from government, academia, integrated health centers, data science, and biopharma will lead a highly interactive exploration of these issues and predict what it will take to realize the role of data science enabling personalized medicine.”
Cancer Commons founder Marty Tenenbaum, PhD, will speak at the upcoming Bridging Clinical Research & Clinical Health Care Collaborative at the National Academy of Sciences in Washington, DC, on March 4 at 5:00 pm. Marty, who founded Cancer Commons after his own battle with melanoma, will facilitate an expert panel discussion on “Reinventing Clinical Research and Cancer Care.” That same day, he will also lead a lunchtime discussion on “Shifting the Clinical Trials Paradigm From Approving Drugs to Curing Patients.”
In preparation for the conference, Marty has written a piece for Bridging Clinical that outlines his take on the increasing demand for patients in clinical research. An excerpt: “Those familiar with the current drug development process express skepticism that the system can ever be changed — and for good reason; many have tried and failed. However, a confluence of trends, from patient activism to the explosion of new therapies to an unprecedented open regulatory environment, make a paradigm shift from drug-developer-centric to patient-centric trials both necessary and possible.” Click here to read the full article.
Cancer Commons founder Marty Tenenbaum, PhD, will speak at the NYC Oncology Investor Conference on October 30. Marty, who founded Cancer Commons after his own battle with melanoma, will discuss the potential for artificial intelligence to help find better cancer treatments.
Read the synopsis of Marty’s presentation, “Can AI Cure Cancer?”: No one knows the optimal way to treat any cancer with currently available therapies. When clinical advances are made, it can take years for you and your doctor to find out about them. Getting access to breakthrough therapies, in a clinical trial or through expanded access, is problematic. Developing a new drug from scratch can take a decade or more and cost upwards of a billion dollars. AI can help. I will outline a plan, with the potential to save many thousands of lives, and a strategy for funding it through philanthropy and impact investing.
The NYC Oncology Investor Conference brings together “leading life science and oncology venture capitalists, family offices, lawyers, pharma executives, startup public and private cancer companies, and cancer foundations for a discussion of trends, opportunities, and risks in oncology investing, corporate presentations by a select group of public and private oncology companies, and updates on cutting edge science.”
Cancer Commons founder Marty Tenenbaum, Ph.D., will speak at the upcoming Bio-IT World Conference & Expo in Boston, which runs May 15 to 18. Marty, who founded Cancer Commons after his own battle with melanoma, will discuss the potential for artificial intelligence to help find better cancer treatments.
AI can beat go and drive cars, but can it beat cancer? Every year, many thousands of cancer patients die unnecessarily because their doctors do not know the optimal way to treat them with currently available therapies. Physicians and patients alike struggle with information overload and conflicting expert opinions in making treatment decisions. Moreover, effective treatments increasingly involve intelligently designed, individually tailored, sequences and combinations, and there are far more plausible multi-drug regimens than can be efficiently tested in clinical trials. AI can help by connecting physicians and patients to the right information at the right time, and by planning and coordinating the thousands of formal and informal treatment experiments that take place daily in oncology, to optimize individual outcomes and maximize collective knowledge. We will describe a developing global collaboration to realize this bold vision, involving leading oncologists, cancer and data scientists, and AI experts from both academia and industry, and discuss opportunities for all to participate.
The Bridging Clinical Research & Clinical Health Care Collaborative is “the only forum where clinical research and health care professionals come together to envision a collaborative solution that strengthens the connection between clinical research and health care.” Learn more about the event at https://www.bridgingclinical.com/agenda/.
Cancer Commons founder Marty Tenenbaum, Ph.D., will speak at the upcoming Precision Medicine World Conference (PMWC) in Durham, NC, which runs May 24–25. Marty, who founded Cancer Commons after his own battle with melanoma, will discuss the organization’s ongoing efforts to address challenges to knowledge-sharing in precision oncology.
Read the synopsis of Marty’s presentation, entitled “Is An Additional Path to FDA Approval Possible?”:
This talk will explore the question: When faced with certain death, it is acceptable to accept less than 100% proven safety and efficacy?Patients with glioblastoma and certain other cancers with dire prognoses do not have the time to wait for new treatments to be fully approved by the FDA. Is it time to add “conditional approval” as an additional pathway to approval for these patients? In this session, a plan will be proposed by which the FDA could conditionally approve a treatment that has been proven safe in a clinical trial(s) with at least 25 patients, and has demonstrated biologic activity. Therefore, this treatment could not be denied by insurance as being “experimental”. However, the requires patients using these drugs to participate in a registry through which their physicians submit details on the treatments, side effects and outcomes. The FDA’s periodic review of the registry data would lead to a range of outcomes from full approval to the conditional approval being revoked.
Marty’s talk takes place on May 24 at 2:45 pm. For more information, visit the PMWC website.
Oncologist and Cancer Commons Medical Director Kevin Knopf, MD, will speak next month at TiEcon 2017, a technology conference in Santa Clara, CA. He’ll join three other experts to discuss the future of personalized medicine. From the program:
A new era of personalized medicine has made its way into the world of healthcare. We will discuss novel approaches for designing disease treatment and prevention that integrates with an individual’s genetic profile, environment and lifestyle.The future is here — let’s hear from industry luminaries on how digital health entrepreneurs and the healthcare industry as a whole are preparing for massive disruption.
Kevin’s presentation will take place on May 5 at 3:00 pm. For more information, visit the TiEcon website.
This year, the Annual Meeting of the American Society of Clinical Oncology (ASCO) did not produce any truly groundbreaking revelations about new treatments for lung cancer. However, researchers did report quite a few positive findings, and some disappointing ones. I have summarized some of the more prominent presentations below. Continue reading…